Immutep (IMMP) Other Non-Current Assets (2014 - 2025)
Immutep's (IMMP) quarterly Other Non-Current Assets came in at $93079.4 in Q4 2025, up 31.0% YoY from $71054.3 in Q4 2024, and up 24.61% on a QoQ basis from $74697.6 in Q2 2025.
Immutep (IMMP) Other Non-Current Assets (2014 - 2025) Analysis & Trends
Immutep (IMMP) has 10 years of Other Non-Current Assets data on file, last reported at $93079.4 in Q4 2025.
- Quarterly Other Non-Current Assets rose 31.0% year-over-year to $93079.4 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $93079.4 (up 31.0% YoY) and the FY2025 annual result came in at $74697.6, down 91.34% from the prior year.
- Other Non-Current Assets climbed to $93079.4 in Q4 2025, from $74697.6 in the prior quarter.
- In the past five years, Other Non-Current Assets ranged from a high of $1.7 million in Q2 2023 to a low of $71054.3 in Q4 2024.
- A 5-year average of $496478.2 and a median of $346288.3 in 2021 frame the typical range for Other Non-Current Assets.
- Annual changes were most pronounced in 2021 — Other Non-Current Assets jumped 1109.63% — and 2025, when it plunged 91.34%.
- Tracing IMMP's Other Non-Current Assets over 5 years: stood at $342825.2 in 2021, then retreated by 1.57% to $337431.9 in 2022, then jumped by 134.49% to $791243.8 in 2023, then slumped by 91.02% to $71054.3 in 2024, then soared by 31.0% to $93079.4 in 2025.
- The last three Other Non-Current Assets figures came in at $93079.4 (Q4 2025), $74697.6 (Q2 2025), and $71054.3 (Q4 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 124.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 618.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 109.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 65.13 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 202.31 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 104.44 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 62.96 Mn |
| 10 | Immutep | 56.46 Mn | -8.63 Mn | - | 93,079.43 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 93,079.43 |
| Jun 30, 2025 | 74,697.57 |
| Dec 31, 2024 | 71,054.35 |
| Jun 30, 2024 | 862,121.99 |
| Dec 31, 2023 | 791,243.78 |
| Jun 30, 2023 | 1.69 Mn |
| Dec 31, 2022 | 337,431.94 |
| Jun 30, 2022 | 355,025.56 |
| Dec 31, 2021 | 342,825.16 |
| Jun 30, 2021 | 349,751.34 |
| Dec 31, 2020 | 28,341.26 |
| Dec 31, 2019 | 27,690.33 |
| Jun 30, 2019 | 40,041.80 |
| Mar 31, 2017 | 23,199.26 |
| Jun 30, 2016 | 23,065.64 |
| Dec 31, 2014 | 207.01 Mn |
| Jun 30, 2014 | 1.20 Mn |